Please login to the form below
TDF
This page shows the latest TDF news and features for those working in and with pharma, biotech and healthcare.
GSK’s ViiV submits application for cabotegravir to EMA for HIV-1 prevention
The studies demonstrated that cabotegravir long-acting for PrEP was superior to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), with clinical trial participants experiencing a 69% lower rate of HIV ... acquisition compared to FTC/TDF
Latest news
-
Gilead set to acquire hepatitis specialist MYR for €1.15bn
In the phase 2 MYR202 study, 54 of 90 patients treated with Hepcludex and tenofovir disoproxil fumarate (TDF) had at least a 2 log10 HDV RNA decline or undetectable HDV RNA
-
Positive trial results for Janssen’s Symtuza boosts its HIV credentials
laboratory parameters compared to F/TDF (emtricitabine/tenofovir disproxil fumarate). ... TDF - in HIV-1 positive treatment-naïve adult patients.
-
Gilead's Hepatitis B therapy Vemlidy granted EU approval
Vemlidy (tenofovir alafenamide, TAF) is a once-daily oral treatment, and produces a similar antiviral efficacy to its predecessor Viread (tenofovir disoproxil fumarate, TDF) but at only 10% of the dosage. ... With less tenofovir in the bloodstream, TAF
-
Gilead gets EU nod for TAF-based triple therapy for HIV
It is a follow up to Gilead's $1.4bn Complera, which contains emtricitabine, rilpivirine and tenofovir disoproxil fumarate (TDF) and is among the most prescribed HIV drugs. ... TAF is a new salt form of TDF that is ten-fold more potent and can be
-
Gilead bags EU approval for next-generation HIV drug
Clinical trials have shown that TAF is safer than TDF in terms of renal toxicity and bone demineralisation, to recognised toxicities associated with the original drug. ... Gilead is in the process of replacing all its TDF-based HIV drugs with TAF
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Choices, choices: the rapidly evolving HIV treatment landscape
Gilead, in hot pursuit, is in phase III of development of a new regimen where TDF has been substituted with tenofovir alafenamide fumarate (TAF). ... TAF is more potent than TDF and can be administered at a much lower dose, dramatically reducing side
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
What about me? Human centricity rather than patient centricity…
The Theoretical Domains Framework (TDF) 1 has a number of key tenets that relate to the sense of self in terms of social and professional role and identity, but also beliefs
-
Frontera Group
TDF behaviour decoding. COM-B behavioural analysis. HACKATHON: events with disease communities. MAP: market and competitor analysis.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Medscape Medical Affairs
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
